Table 3. . Sensitivity analysis results for costs per patient over a 15-year time horizon for all first-line and second-line treatments without treatment switching or delay.
| Treatment | Non-disease modifying therapy costs† | |
|---|---|---|
| Absolute cost | Incremental cost of ofatumumab vs comparator | |
| First-line therapies | ||
| Ofatumumab | $177,808 | – |
| Ocrelizumab | $182,956 | $5148 |
| Teriflunomide | $222,578 | $44,770 |
| Dimethyl fumarate | $207,828 | $30,020 |
| Glatiramer acetate | $219,234 | $41,427 |
| Avonex | $219,945 | $42,137 |
| Rebif 44 | $221,279 | $43,471 |
| Betaseron | $219,907 | $42,099 |
| Extavia | $219,907 | $42,099 |
| BSC | $246,279 | $68,471 |
| Second-line therapies | ||
| Cladribine | $195,163 | $17,355 |
| Natalizumab | $182,289 | $4482 |
| Fingolimod | $204,538 | $26,730 |
†
Results for administration and monitoring costs are not presented for the 15-year analysis as they do not change from the 10-year results.
BSC: Best supportive care.